QbD-driven development of intranasal lipid nanoparticles for depression treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/90817 https://doi.org/10.1016/j.ejpb.2020.04.011 |
Resumo: | Depression is a life-threatening psychiatric disorder and a multifactorial global public health concern. Current pharmacological treatments present limited efficacy, and are associated with several harmful side effects and development of pharmacoresistance mechanisms. Developing more effective therapeutic options is therefore a priority. This work aims at efficiently designing an antidepressant therapeutic surrogate relying on a dual strategy supported on lipid nanoparticles and intranasal delivery. For that purpose, the formulation was comprehensively optimized following a quality by design perspective. Critical quality attributes (CQAs) ranged from physicochemical to intranasal performance features. The optimized formulation was administered to mice in order to assess the antidepressive and anxiolytic effects by applying the forced swimming and marble-burying tests, respectively. A cross-analysis of the predictive models established for the set of 12 CQAs elicited the formulation containing similar proportion of solid and liquid lipids and lower surfactant concentration as the optimal one. Despite increasing the liquid lipid amount yielded smaller and more homogeneous particle size, and higher release rate, nanostructured lipid carriers (NLCs) provided an earlier and superior pig nasal mucosa permeability than nanoemulsions, along with better stability and cytotoxic profiles. Importantly, the intranasal delivery of the optimal lipid nanoparticle formulation reduced both depressive and anxiety-like behaviors, which positions these intranasal nanosystems in line with the hypothesis of provisioning timely and better acting antidepressant therapies. |
id |
RCAP_d1754272a3433daae63d8fcfce48c3fd |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/90817 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
QbD-driven development of intranasal lipid nanoparticles for depression treatmentDepressionFluoxetineIn vivo behavioral studiesIntranasalNanoparticlesNasal mucosaNose-to-brainQuality by design approachDepression is a life-threatening psychiatric disorder and a multifactorial global public health concern. Current pharmacological treatments present limited efficacy, and are associated with several harmful side effects and development of pharmacoresistance mechanisms. Developing more effective therapeutic options is therefore a priority. This work aims at efficiently designing an antidepressant therapeutic surrogate relying on a dual strategy supported on lipid nanoparticles and intranasal delivery. For that purpose, the formulation was comprehensively optimized following a quality by design perspective. Critical quality attributes (CQAs) ranged from physicochemical to intranasal performance features. The optimized formulation was administered to mice in order to assess the antidepressive and anxiolytic effects by applying the forced swimming and marble-burying tests, respectively. A cross-analysis of the predictive models established for the set of 12 CQAs elicited the formulation containing similar proportion of solid and liquid lipids and lower surfactant concentration as the optimal one. Despite increasing the liquid lipid amount yielded smaller and more homogeneous particle size, and higher release rate, nanostructured lipid carriers (NLCs) provided an earlier and superior pig nasal mucosa permeability than nanoemulsions, along with better stability and cytotoxic profiles. Importantly, the intranasal delivery of the optimal lipid nanoparticle formulation reduced both depressive and anxiety-like behaviors, which positions these intranasal nanosystems in line with the hypothesis of provisioning timely and better acting antidepressant therapies.Elsevier2020-08info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/90817http://hdl.handle.net/10316/90817https://doi.org/10.1016/j.ejpb.2020.04.011eng09396411https://www.sciencedirect.com/science/article/pii/S0939641120301053Vitorino, CarlaSilva, SoraiaGouveia, FilipaBicker, JoanaFerreira, Amílcar Celta Falcão RamosFortuna, Ana Cristina Bairradainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-05-25T06:23:16Zoai:estudogeral.uc.pt:10316/90817Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:10:50.529304Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
title |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
spellingShingle |
QbD-driven development of intranasal lipid nanoparticles for depression treatment Vitorino, Carla Depression Fluoxetine In vivo behavioral studies Intranasal Nanoparticles Nasal mucosa Nose-to-brain Quality by design approach |
title_short |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
title_full |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
title_fullStr |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
title_full_unstemmed |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
title_sort |
QbD-driven development of intranasal lipid nanoparticles for depression treatment |
author |
Vitorino, Carla |
author_facet |
Vitorino, Carla Silva, Soraia Gouveia, Filipa Bicker, Joana Ferreira, Amílcar Celta Falcão Ramos Fortuna, Ana Cristina Bairrada |
author_role |
author |
author2 |
Silva, Soraia Gouveia, Filipa Bicker, Joana Ferreira, Amílcar Celta Falcão Ramos Fortuna, Ana Cristina Bairrada |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Vitorino, Carla Silva, Soraia Gouveia, Filipa Bicker, Joana Ferreira, Amílcar Celta Falcão Ramos Fortuna, Ana Cristina Bairrada |
dc.subject.por.fl_str_mv |
Depression Fluoxetine In vivo behavioral studies Intranasal Nanoparticles Nasal mucosa Nose-to-brain Quality by design approach |
topic |
Depression Fluoxetine In vivo behavioral studies Intranasal Nanoparticles Nasal mucosa Nose-to-brain Quality by design approach |
description |
Depression is a life-threatening psychiatric disorder and a multifactorial global public health concern. Current pharmacological treatments present limited efficacy, and are associated with several harmful side effects and development of pharmacoresistance mechanisms. Developing more effective therapeutic options is therefore a priority. This work aims at efficiently designing an antidepressant therapeutic surrogate relying on a dual strategy supported on lipid nanoparticles and intranasal delivery. For that purpose, the formulation was comprehensively optimized following a quality by design perspective. Critical quality attributes (CQAs) ranged from physicochemical to intranasal performance features. The optimized formulation was administered to mice in order to assess the antidepressive and anxiolytic effects by applying the forced swimming and marble-burying tests, respectively. A cross-analysis of the predictive models established for the set of 12 CQAs elicited the formulation containing similar proportion of solid and liquid lipids and lower surfactant concentration as the optimal one. Despite increasing the liquid lipid amount yielded smaller and more homogeneous particle size, and higher release rate, nanostructured lipid carriers (NLCs) provided an earlier and superior pig nasal mucosa permeability than nanoemulsions, along with better stability and cytotoxic profiles. Importantly, the intranasal delivery of the optimal lipid nanoparticle formulation reduced both depressive and anxiety-like behaviors, which positions these intranasal nanosystems in line with the hypothesis of provisioning timely and better acting antidepressant therapies. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-08 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/90817 http://hdl.handle.net/10316/90817 https://doi.org/10.1016/j.ejpb.2020.04.011 |
url |
http://hdl.handle.net/10316/90817 https://doi.org/10.1016/j.ejpb.2020.04.011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
09396411 https://www.sciencedirect.com/science/article/pii/S0939641120301053 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134004169932800 |